Introduction: The Double-Edged Sword of Biological Innovation
In the heart of the COVID-19 pandemic, the world witnessed a modern miracle. Leveraging revolutionary mRNA technology, scientists developed, tested, and deployed highly effective vaccines in under a year—a feat that would have been pure science fiction just a decade prior. This triumph was a stark demonstration of biotechnology’s immense power to safeguard humanity. Yet, this same explosion of biological capability carries with it a profound and unsettling reality: the very tools that can save us can also be used, intentionally or accidentally, to cause unprecedented harm. We have entered a new era, one defined not by the simple “dual-use” dilemma of the 20th century, but by the far more complex and pervasive challenge of “omni-use” biotechnology.
As highlighted in recent analyses from institutions like the Sasakawa Peace Foundation, these are technologies without borders. The power to read, write, and edit the code of life is no longer confined to superpower states or elite research institutions. It is becoming democratized, digitized, and distributed globally, flowing across a borderless internet and through complex international supply chains. This diffusion of power is rapidly outpacing the international treaties and national regulations designed in a bygone era. The result is a growing governance void, a dangerous gap between our technological capabilities and our collective ability to manage them responsibly. This article delves into the nature of this omni-use revolution, explores the profound governance challenges it presents, and considers the urgent need for a new global framework to navigate this uncharted territory.
The Dawn of Omni-Use: Beyond the Dual-Use Dilemma
For decades, the international security community has been preoccupied with “dual-use” technologies—those with clear civilian and military applications. Nuclear energy could power a city or destroy it. Chemical precursors could be used for fertilizer or for chemical weapons. This binary framework, however, is increasingly inadequate for understanding the landscape of modern biotechnology.
From Dual-Use to Omni-Use: A Fundamental Paradigm Shift
The concept of “omni-use” more accurately captures the multifaceted nature of today’s biological tools. A technology like the CRISPR-Cas9 gene-editing system is not simply dual-use; its potential applications span a vast, continuous spectrum. At one end lies immense benefit: curing hereditary diseases like sickle cell anemia, engineering crops to withstand climate change, and developing novel therapeutics. In the middle are ethically grey areas, such as human enhancement or purely cosmetic genetic modifications. At the far end of the spectrum lies catastrophic risk: creating more virulent or transmissible pathogens, developing targeted bioweapons, or accidentally releasing an engineered organism that could devastate an ecosystem.
Unlike a nuclear weapon, which requires massive infrastructure and rare materials, the tools of biotechnology are fundamentally based on information. The “weapon” is not a physical object but the knowledge of how to manipulate a biological system. This knowledge can be applied in countless ways, by countless actors, for countless purposes—good, bad, and indifferent. This is the essence of the omni-use challenge: a single technology has a near-infinite application space, making its intent and ultimate impact incredibly difficult to predict, classify, or control through traditional means.
The Engines of the Revolution: Key Enabling Technologies
This new era is not driven by a single breakthrough but by the convergence of several powerful technological currents. Three stand out as primary engines of the omni-use revolution:
- Gene Editing Tools (e.g., CRISPR-Cas9): Often described as “molecular scissors,” CRISPR allows scientists to make precise changes to the DNA of living organisms with unprecedented ease and low cost. Its discovery has supercharged research across all life sciences. The same technique used in a university lab to study cancer genetics could theoretically be used by a non-state actor to increase the pathogenicity of a common virus. Its simplicity and accessibility are both its greatest strength and its most significant liability.
- Synthetic Biology: Moving beyond merely editing existing genomes, synthetic biology applies engineering principles to biology. It enables scientists to design and construct new biological parts, devices, and systems from the ground up. This includes synthesizing entire viral genomes from scratch based solely on digital sequence data. Companies can now “print” DNA on demand, a service that dramatically accelerates legitimate research but also creates a potential pathway for malicious actors to acquire the genetic material for dangerous pathogens without needing a physical sample.
- Artificial Intelligence and Machine Learning (AI/ML): AI is the accelerant poured on the fire of the biotech revolution. AI algorithms can now analyze vast biological datasets to predict protein structures (as demonstrated by DeepMind’s AlphaFold), design entirely new enzymes, and identify novel drug candidates in a fraction of the time required by human researchers. However, this same predictive power can be turned to nefarious purposes. In one chilling proof-of-concept study, researchers retrained an AI model normally used for discovering non-toxic medicines and, within six hours, it generated 40,000 potential chemical warfare agents, including known nerve agents and many novel, even more toxic compounds.
Technologies Without Borders: The Globalization of Bio-Power
The governance challenge is compounded by a second fundamental reality: these technologies are inherently borderless. The physical, legal, and institutional barriers that once contained advanced scientific capabilities are rapidly eroding, creating a truly globalized and decentralized ecosystem of biological innovation and risk.
The Democratization of the Laboratory
The cost of the core tools of biotechnology has plummeted over the past two decades. The price of sequencing a human genome has fallen from nearly $100 million in the early 2000s to under $1,000 today. Basic laboratory equipment like PCR machines and DNA synthesizers, once the exclusive domain of major research universities and corporations, are now affordable enough for small startups, community labs, and even well-resourced individuals.
This has fueled the rise of the “DIY biology” or “biohacker” movement—a global community of amateur and independent scientists conducting biological experiments outside of traditional institutional settings. While the vast majority of these enthusiasts are driven by curiosity and a desire to do good, the trend signifies a broader decentralization of technical capacity. The ability to perform sophisticated genetic engineering is no longer limited to professionals who are bound by institutional oversight and ethical review boards.
The Digital Backbone of Modern Biology
At its core, modern biology is becoming an information science. A genome is a digital file. A protein’s structure is a set of coordinates. A lab protocol is a text document. This digitization means that the most critical components of biotechnology can be shared instantly and globally with a simple email or a download from a public database like GenBank.
This creates a profound security dilemma. Efforts to classify the full genome of the 1918 Spanish Flu virus or to reconstruct the horsepox virus (a relative of smallpox) were undertaken for legitimate scientific reasons—to understand pandemic threats and develop new vaccines. However, once published, that information is available to anyone with an internet connection. It is impossible to “un-publish” a genetic sequence. This means that containing a dangerous piece of biological information is exponentially more difficult than containing a physical material like plutonium.
Global Supply Chains and the Challenge of Intangible Transfer
The physical components of biotechnology—reagents, enzymes, and custom-synthesized DNA—are sourced through complex, international supply chains. A lab in one country might design a genetic construct, email the digital file to a synthesis company in a second country, which then manufactures the physical DNA and ships it to a third country for experimentation.
This complicates traditional export controls, which were designed to track the movement of physical goods. The most valuable transfer—the “intangible technology transfer” of knowledge and digital designs—often happens before any physical item crosses a border. While some leading DNA synthesis companies voluntarily screen orders against databases of dangerous pathogens, this is not a universal practice, and enforcement is inconsistent across different jurisdictions. A determined actor could easily split orders among different companies or make slight modifications to a sequence to evade detection, making this a porous and easily circumvented line of defense.
The Governance Void: Navigating a World of Unprecedented Risk
This confluence of omni-use potential and borderless diffusion has placed immense strain on our existing governance structures. The legal and diplomatic instruments we rely on to manage global threats were created for a world of state actors, physical materials, and clear distinctions between peaceful and military activities. They are ill-equipped for the fluid, fast-moving, and ambiguous challenges of 21st-century biotechnology.
The Strain on Existing Frameworks
The primary international treaty governing this space is the 1975 Biological Weapons Convention (BWC). The BWC is a cornerstone of the global non-proliferation regime, categorically banning the development, production, and stockpiling of biological weapons. However, it has two critical weaknesses in the modern era. First, it lacks any formal verification or inspection mechanism, relying instead on the trust and self-reporting of its member states. Second, it was designed to address state-level bioweapons programs. It has little to say about the risks posed by non-state actors, individual biohackers, or even accidental releases from legitimate research gone awry.
National regulations are a fragmented patchwork. Some countries have robust biosafety and biosecurity oversight systems, while others have virtually none. This creates the risk of “governance havens,” where researchers or companies can conduct high-risk experiments with minimal scrutiny, potentially endangering the entire global community. Similarly, multilateral export control regimes like the Australia Group, which aim to prevent the spread of materials and equipment for chemical and biological weapons, struggle to keep pace. They are effective at controlling lists of specific pathogens and equipment but find it nearly impossible to regulate the underlying omni-use technologies (like CRISPR) or the intangible transfer of digital information.
The Great Trilemma: Balancing Speed, Safety, and Equity
Policymakers face an inherent “trilemma” in governing biotechnology. They must simultaneously try to achieve three competing goals:
- Promote Innovation Speed: Society has a clear interest in accelerating biotechnological progress to develop new medicines, secure our food supply, and create sustainable energy sources. Overly burdensome regulation can stifle this innovation.
- Ensure Safety and Security: It is imperative to prevent catastrophic accidents (biosafety) and deliberate misuse (biosecurity). This requires careful oversight, risk assessment, and controls.
- Foster Equitable Access: The immense benefits of biotechnology should not be confined to wealthy nations. There is a moral and practical imperative to ensure that developing countries can access these tools to address their own health and economic challenges.
The difficulty is that pushing too hard on any one of these goals can compromise the others. Strict security controls might slow down vital research and limit access for poorer nations. A laissez-faire approach to speed up innovation might invite unacceptable risks. A focus on equity without adequate safety standards could lead to the proliferation of dangerous capabilities. Finding a sustainable balance among these three objectives is the central challenge for global governance.
New Specters on the Horizon: Emerging Threats and Grey Areas
The governance void allows several high-consequence risks to fester. These include:
- Engineered Pandemics: The deliberate or accidental creation of a pathogen with enhanced transmissibility or virulence represents arguably the greatest existential threat in this domain. Research known as “Gain-of-Function Research of Concern” (GoFROC), which involves modifying pathogens to study their potential, remains a subject of intense international debate precisely because of this risk.
- Ecological Disruption: Technologies like gene drives, which can spread a genetic modification rapidly through an entire wild population, hold great promise for eradicating disease vectors like mosquitoes or controlling invasive species. However, an uncontrolled release could have irreversible and devastating consequences for entire ecosystems.
- Ethical and Societal Upheaval: Beyond security threats, these technologies raise profound ethical questions. The possibility of human germline editing—making heritable changes to human DNA—could eliminate genetic diseases but also open the door to a new era of eugenics and social stratification. The line between therapy and enhancement is becoming increasingly blurred, forcing societies to confront difficult questions about what it means to be human.
Forging a Path Forward: A New Architecture for Global Bio-Governance
Closing the governance void will not be achieved by a single treaty or a simple set of laws. The diffuse, rapidly evolving nature of omni-use biotechnology demands a more agile, multi-layered, and collaborative approach. The goal must be to foster a global culture of responsibility that permeates every level of the biotech ecosystem, from the individual researcher to international bodies.
Beyond Treaties: A Multi-Layered, Agile Approach
A 21st-century governance architecture must be built on multiple pillars. While strengthening the BWC and harmonizing national regulations are important, they are insufficient on their own. We need to complement these top-down state-led efforts with bottom-up and middle-out approaches. This includes developing flexible international norms, technical standards, and codes of conduct that can adapt more quickly than the slow-moving process of treaty negotiation. It also means investing heavily in global capabilities for pandemic preparedness and response, including advanced surveillance systems for detecting novel biological events and the capacity for rapid attribution to determine their origin, whether natural, accidental, or deliberate.
The Critical Role of the Scientific Community
Scientists and research institutions are the first line of defense. A sense of shared responsibility must be deeply embedded in the culture of science itself. The 1975 Asilomar Conference on Recombinant DNA serves as a powerful historical precedent. There, scientists themselves voluntarily paused their research to debate the risks and establish safety guidelines before any government regulations were in place. A similar spirit is needed today. Scientific academies, universities, and professional societies must take the lead in developing and enforcing robust ethical codes, promoting education on dual-use and omni-use risks, and championing a culture of transparency and responsible innovation.
Harnessing the Power of Public-Private Partnerships
The private sector is a critical actor in the biotech ecosystem. Companies that synthesize DNA, manufacture laboratory equipment, and host cloud-based bioinformatics platforms have unique visibility and leverage points to promote security. Collaborative efforts, such as the International Gene Synthesis Consortium (IGSC), which has developed a harmonized screening protocol to vet customers and orders, are vital. Governments should work to incentivize and expand these private-sector initiatives, creating a partnership where industry becomes a key node in the global biosecurity network, helping to identify and flag suspicious activities without stifling legitimate commerce and research.
Conclusion: The Choice Before Us
The era of omni-use, borderless biotechnology is not a distant future; it is our present reality. We are wielding tools of unprecedented power with a governance framework that is perilously outdated. The challenges are formidable, touching upon international security, economic competitiveness, public health, and the very definition of life itself. Yet, the potential for good is equally immense. The path forward is not to halt progress out of fear, but to accelerate the development of our collective wisdom and governance capacity to match our technical ingenuity. The international community—from policymakers and security experts to individual scientists and corporate leaders—stands at a critical juncture. We must act decisively and collaboratively to build a global framework that can safely and equitably harness the promise of this biological revolution for the betterment of all humanity.
